Highlights and Quick Summary
- Research and Development Expense of Revenue for the quarter ending December 31, 2022 was -39.74% (a -152.65% decrease compared to previous quarter)
- Year-over-year quarterly Research and Development Expense of Revenue decreased by -199.72%
- Annual Research and Development Expense of Revenue for 2022 was 175.29% (a -47.83% decrease from previous year)
- Annual Research and Development Expense of Revenue for 2021 was 335.97% (a 172.61% increase from previous year)
- Annual Research and Development Expense of Revenue for 2020 was 123.24% (a 67.72% increase from previous year)
- Twelve month Research and Development Expense of Revenue ending December 31, 2022 was 175.29% (a 22.24% increase compared to previous quarter)
- Twelve month trailing Research and Development Expense of Revenue decreased by -23.92% year-over-year
Trailing Research and Development Expense of Revenue for the last four month:
| 31 Dec '22 | 30 Sep '22 | 30 Jun '22 | 31 Mar '22 |
|---|---|---|---|
| 175.29% | 143.4% | 234.48% | 230.39% |
Visit stockrow.com/PGEN
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Research and Development Expense of Revenue of Precigen, Inc.
Most recent Research and Development Expense of Revenueof PGEN including historical data for past 10 years.Interactive Chart of Research and Development Expense of Revenue of Precigen, Inc.
Precigen, Inc. Research and Development Expense of Revenue for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | -39.74% | 75.48% | 410.65% | 39.85% | 175.29% |
| 2021 | -67.81% | 373.06% | 345.58% | 42.92% | 335.97% |
| 2020 | -16.31% | 43.13% | 31.14% | 37.96% | 123.24% |
| 2019 | -83.39% | 140.26% | 86.0% | 119.27% | 73.48% |
| 2018 | 617.97% | 138.33% | 92.87% | 93.95% | 220.27% |
| 2017 | 6.91% | 79.26% | 62.48% | 63.59% | 49.75% |
| 2016 | 62.76% | 59.27% | 54.05% | 59.52% | 58.73% |
| 2015 | 63.13% | 40.47% | 45.4% | 234.3% | 84.95% |
| 2014 | 56.73% | 70.06% | 122.46% | 153.53% | 82.0% |
| 2013 | 175.7% | 176.63% | 201.94% | 293.72% | 202.62% |
| 2012 | 491.08% | 647.14% | – | – | 464.89% |
Business Profile of Precigen, Inc.
Sector: Healthcare
Industry: Biotechnology